Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04028492 · ClinicalTrials.gov registry record · Phase 3
Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis
A Phase 3 study, sponsored by Vanda Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 992
- Enrollment target
NCT04028492 is a Phase 3 study that has completed, run by Vanda Pharmaceuticals. The registered enrollment target is 992 participants.
The verdict
NCT04028492, a Phase 3 study, has completed, sponsored by Vanda Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 992 participants
- Enrollment target
Study Summary
To investigate the safety and efficacy of tradipitant versus placebo in relieving nausea and other symptoms of gastroparesis.
Interventions
- DRUG Placebo
- DRUG Tradipitant
- DRUG Open Label Tradipitant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 992 participants |
| Start Date | 2019-08-20 |
| Est. Completion | 2025-02-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04028492
The ClinicalTrials.gov registry entry for NCT04028492 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 992 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanda Pharmaceuticals, which has 68 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04028492 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04028492 about?
NCT04028492 is a clinical study titled "Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis". To investigate the safety and efficacy of tradipitant versus placebo in relieving nausea and other symptoms of gastroparesis.
What is the current status of trial NCT04028492?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 992 participants. The study started on 2019-08-20. Estimated completion is 2025-02-21.
What interventions are being tested in trial NCT04028492?
The interventions under investigation include: Placebo (DRUG), Tradipitant (DRUG), Open Label Tradipitant (DRUG).
Who is sponsoring clinical trial NCT04028492?
This trial is sponsored by Vanda Pharmaceuticals, which has 68 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.